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Tetrahydrobiopterin (BH4) deficiencies are inherited neuro-metabolic disorders leading to
monoamine neurotransmitters deficiency. An individualized replacement therapy with
neurotransmitters precursors is necessary to restore dopaminergic and serotoninergic
homeostasis. The correction of dopaminergic tone is complicated, like in Parkinson dis-
ease, by L-dopa short half-life and adverse effects. To improve this picture, since 2009 we
introduced the non-ergot dopamine agonist pramipexole as an adjunct to L-dopa therapy in
the treatment of the most common causes of BH4 deficiency, 6-pyruvoyl tetrahydropterin
synthase (PTPS) deficiency and dihydropteridine reductase (DHPR) deficiency. In the short-
term period, this approach allowed substantial clinical advantages in affected patients,
with amelioration and stabilization of the clinical picture on twice daily treatment
administration and no adverse effect.
Here we describe the long-term clinical follow-up (83 ± 24 months) of seven patients
with BH4 deficiency treated with pramipexole. After a period of good clinical compensation
(34 ± 1 months), different impulse control disorders (gambling, compulsive buying, and
hypersexuality) were observed in three patients treated with high-dose pramipexole (0.030
e0.033 mg/kg/day) beyond adolescence. These psychiatric adverse effects promptly dis-
appeared after curtailing pramipexole dose by 50e60%. Low-dose pramipexole therapy has
been safe and effective in the long-term period in all treated patients (59 ± 9 months).
High-dose pramipexole therapy in BH4 deficiency can be complicated, like in Parkinson
disease, by psychiatric adverse effects. Low-dose pramipexole therapy (~0.010 mg/kg/day)
has been safe and clinically effective on long-term follow-up, representing a helpful
therapeutic option in patients with BH4 deficiency.
© 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Tetrahydrobiopterin (BH4) deficiencies are a heterogeneous
group of rare inherited neuro-metabolic disorders2.
(F. Porta), fporta@unito.i
logy Society. Published bcharacterized by monoamine neurotransmitters deficiency.
Taken together, 6-pyruvoyl tetrahydropterin synthase defi-
ciency (PTPS; MIM 261640) and dihydropteridine reductase
deficiency (DHPR; MIM 261630) represent about 90% of all
forms of BH4 deficiency. Both conditions result int (A. Ponzone), marco.spada@unito.it (M. Spada).
y Elsevier Ltd. All rights reserved.
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e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 8 3 9e8 4 2840hyperphenylalaninemia and impaired catecholamine and
serotonin neurotransmitter production. Clinical presentation
occurs soon after birth or after some months, with neurolog-
ical deterioration, developmental delay, seizures, truncal hy-
potonia and limb hypertonia, associated with parkinsonian
features. Early diagnosis is facilitated by neonatal screening
for hyperphenylalaninemia and prompt treatment essential
for patients' outcome.1e3 Standard therapy is very complex.
The administration of synthetic BH4 allows the correction of
peripheral hyperphenylalaninemia, but scarce effects can be
obtained at the central level. An individualized neurotrans-
mitters replacement therapy is necessary to restore dopami-
nergic and serotoninergic homeostasis. The correction of
dopaminergic neurotransmission represents the most critical
aspect in BH4 deficiency, mainly due to L-3,4 dihydrox-
yphenylalanine (L-dopa) short half-life and adverse effects.
Three to six daily L-dopa administrations are generally
necessary for a satisfactory clinical compensation, even if
inhibitors of L-dopa catabolism, such as carbidopa, deprenyl
and entacapone are concomitantly administered.1 To improve
this picture, in 2009 we introduced the non-ergot dopamine
agonist pramipexole as an adjunct to L-dopa therapy in a se-
ries of patients with PTPS deficiency, and in 2012 in DHPR
deficiency.4,5 Here we provide the long-term safety and
effectiveness of this implemented therapeutic regimen in BH4
deficiency.ti
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.72. Patients and methods
Seven patientswith BH4 deficiency receiving pramipexole as an
adjunct to L-dopa therapy were clinically followed for 83 ± 24
months. Their characteristics and actual dopaminergic regi-
mens are reported in Table 1. Folinic acid supplementationwas
administered in patients with DHPR deficiency. Satisfactory
control of peripheral hyperphenylalaninemia was obtained in
all patients (mean blood phenylalanine 3.7± 1.8mg/dl). Clinical
visits were scheduled every 3e6 months on the basis of
patients' age and therapeutic response. In all patients, full
clinical evaluation was regularly accomplished also by
applying an adapted Unified Parkinson's Disease Rating
Scale (UPDRS). The occurrence of any side effect related to
pramipexole therapy was systematically investigated.T
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53. Results
In all patients, all the previously described advantages of the
implemented L-dopa þ pramipexole therapy, including the
amelioration and stabilization of the clinical picture on twice
daily treatment administration, were maintained during the
longitudinal clinical monitoring.4,5 On long-term follow-up, no
patients experienced any common side effect of pramipexole
therapy, including dizziness, fainting, drowsiness, visual hal-
lucinations, nausea, weakness, and constipation. After a
variable period of good clinical compensation, however,
older patients treated with high pramipexole dosage
(0.030e0.033 mg/kg/day) experienced different psychiatric side
effects (impulse control disorders) referable to pramipexole
therapy. These adverse effects were invariably associated with
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 8 3 9e8 4 2 841steadily normal prolactin. Prompt reduction of pramipexole
dose to 0.008e0.017 mg/kg/day in all but one patients allowed
the disappearance of the impulse control disorders, subse-
quently warranting a steady optimization of patients' clinical
picture. Patients' clinical reports are described below.
3.1. Patient 1 (PTPS deficiency)
This male patient attended normal school classes and worked
as a barman. Pramipexole (0.033 mg/kg/day) was beneficial
and well tolerated for 34 months, allowing substantial
amelioration of motor and intellectual performances (UPDRS
12/147) as well as improvement of patient's social andworking
life. After this period, the patient experienced compulsive
gambling. The immediate suspension of pramipexole therapy
and re-introduction of standard L-dopa therapy was accom-
panied by disappearance of the addiction but reappearance of
motor disturbances (UPDRS 25/147) and highly fluctuant
hyperprolactinemia. Pramipexole was not re-introduced in
this patient.
3.2. Patient 2 (PTPS deficiency)
This young man was able to attend normal school classes, to
drive a car, tomake sports (horse-riding), and towork as a civil
servant. Pramipexole (0.033 mg/kg/day) warranted good clin-
ical compensation with no reported side effects for 35 months
(UPDRS 17/147). After this period, the patient experienced
episodes of compulsive shopping. The temporary suspension
of the L-dopa þ pramipexole regimen allowed the immediate
disappearance of the impulse control disorder, but worsening
clinical and biochemical compensation (UPDRS 30/147). Pra-
mipexole was then progressively re-introduced at lower dose
(0.013 mg/kg/day). The patient showed optimal clinical
compensation (UPDRS 17/147) with no behavioural distur-
bances neither other side effects until present (61 months
follow-up).
3.3. Patient 3 (PTPS deficiency)
This male patient is severely mentally retarded. He can walk,
run, and attend activities of daily living, but his cognitive
ability is very poor. Pramipexole therapy (0.032 mg/kg/day)
was beneficial and well tolerated for 33 months (UPDRS 40/
143). After this period, parents reported episodes of hyper-
sexuality, aggressivity, and trouble sleeping. These episodes
disappeared after the reduction of pramipexole dose to
0.006 mg/kg/day, with optimized clinical compensation
(UPDRS 40/143) during the next 65 months follow-up.
3.4. Patient 4 and 5 (PTPS deficiency)
These siblings are attending normal school classeswith partial
educational support. In both patients, clinical benefits of pra-
mipexole (0.030 mg/kg/day) were not complicated by any
adverse effect. Based on the clinical experience of behavioural
disturbances in older PTPS patients receiving pramipexole at
the same dose, pramipexole dose was reduced in both patients
(0.008 and 0.009mg/kg/day)with optimal clinical outcome after
100 months follow-up (UPDRS 6/147 and 6/143, respectively).3.5. Patient 6 (DHPR deficiency)
This male patient attended regular school classes and is an
office worker. Clinical advantages of pramipexole mono-
therapy lasted for 30 months with no adverse effects (UPDRS
8/147). Episodes of painful foot dystonia then complicated the
picture. After the reintroduction of a combined L-
dopa þ pramipexole regimen, no further adverse effects were
observed for in the next 44 months (UPDRS 8/147).
3.6. Patient 7 (DHPR deficiency)
This patient is attending normal school classes. After 75
months follow-up, treatment with pramipexole (0.031 mg/kg/
day) was not complicated by any adverse effect (UPDRS 4/147).
To prevent any clinical symptoms of dopaminergic over-
stimulation, pramipexole dose was set at 0.017 mg/kg/day
with stable clinical compensation and no adverse effects.4. Discussion
The correction of dopaminergic homeostasis in BH4 deficiency
is complicated, like in Parkinson disease, by L-dopa pharma-
cokinetics and adverse effects. During last years, we intro-
duced different treatment implementations to ameliorate the
clinical outcome of patients with BH4 deficiency, including the
use of monoamine oxidase inhibitors and catechol-O-
methyltransferase inhibitors.6,7 These drugs allowed signifi-
cant clinical improvement in BH4 deficiency, with reduction of
L-dopa daily dose by 15e20%. In particular, entacaponemainly
exerts its advantageous effect by reducing 3-O-methyldopa
concentration and increasing L-dopa bioavailability without
any increase of peak plasma L-dopa concentration.7
Despite these L-dopa sparing strategies, however, diurnal
fluctuations of the clinical picture and a number of residual
motor and behavioural disabilities are commonly reported.8,9
Since dopamine agonists provide a more continuous dopami-
nergic stimulation with respect to L-dopa, we firstly proposed
and successfully introduced their use in patients with BH4
deficiency.4,5 Pramipexole was chosen because of its docu-
mented effectiveness and safety in Parkinson disease,10 pre-
vious use in pediatrics,11 long half-life (8e12 h),12 low risk of
heart valve and retroperitoneal fibrosis as a non-ergot agent.
We already described the short-term clinical advantages of its
use as an adjunct to L-dopa therapy in BH4 deficiency.
4,5
In this article, we reported the long-term follow-up of pa-
tients with BH4 deficiency receiving pramipexole. After
several months of good clinical compensation, clinical course
in young men with BH4 deficiency on high-dose pramipexole
therapy was complicated by different impulse control disor-
ders, including pathological gambling, compulsive buying,
and hypersexuality. These adverse effects were likely linked
to dopaminergic overstimulation, as promptly resolved by
curtailing by 50e60% the dose of the dopamine agonist.
Actually, such a lowered pramipexole dose was well tolerated
and effective even on long-term follow-up.
Impulse controls disorders became a well known compli-
cation of the use of dopamine agonists in Parkinson dis-
ease.13e16 Although these psychiatric side effects can be
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 8 3 9e8 4 2842associated to the use of different dopamine-agonists, prami-
pexole is the medication predominantly implicated. In Par-
kinson disease, the onset of impulse control disorders often
occurs within the first few months of pramipexole therapy,
although longer latencies (24e30 months) were reported as
well.13 Symptoms generally resolve shortly after stopping the
drug. Pramipexole-associated impulse control disorders,
moreover, were also reported in restless legs syndrome.17
Themolecularmechanism at the basis of these behavioural
adverse effects lies in dopaminergic sensitization. D2 and D3
receptors are the primary molecular targets of the main dopa-
mine agonists, including pramipexole. The wide-spread distri-
bution of D3 receptors within the limbic system suggests their
primary implication on clinically relevant behavioural distur-
bances. Prolonged stimulation by pramipexole of the high-
affinity D3 receptors is associated to an increase in the num-
ber of D3 receptors and an increase of repetitive behaviours in
animal models, and impulse control disorders in humans.18
These mechanisms are likely at the basis of the occurrence of
impulse control disorders even in inherited monoamine
neurotransmitter disorders treated with dopamine agonists.
This is the first report of psychiatric adverse effects related
to the use of dopamine agonists in BH4 deficiency. The
occurrence of compulsive behavioural disturbances was
invariably evidenced after a prolonged period of optimal
clinical compensation. Moreover, the pramipexole-related
impulse control disorders were dose-dependent, as lowering
pramipexole dose was effective in their stable resolution and
prevention. Noteworthy, good clinical compensation on twice
daily treatment administration was possible even after the
curtailment of pramipexole therapy. The optimization of
pramipexole dose in BH4 deficiency, indeed, can be facilitated
by the evaluation of a prolactin profile besides clinical as-
sessments, potentially functional to identify dopaminergic
overstimulation with risk of behavioural side effects.19,20
In conclusion, clinical benefits of the use of high-dose
pramipexole in BH4 deficiency beyond the adolescence can
be complicated, like in Parkinson disease, by the occurrence of
psychiatric behavioural adverse effects. Low-dose pramipex-
ole therapy (~0.010 mg/kg/day) has been safe and effective on
long-term follow-up, representing a helpful therapeutic op-
tion in patients with BH4 deficiency.Conflict of interest statement
All authors have no conflict of interest to declare.r e f e r e n c e s
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